Blueprint Medicines Stock: Rampant Growth Mostly Priced In (NASDAQ:BPMC)

hyejin kang/iStock via Getty Images This is my initial Blueprint Medicines (NASDAQ:BPMC) article. Blueprint is a commercial stage biotech which is pegging potential blockbuster revenues for AYVAKIT/AYVAKYT (avapritinib), its one FDA approved product. With its hefty market cap anticipating its exceptional performance. I rate it a “hold”. For more risk tolerant investors, there is still…

Read More

Atlassian’s Cloud Segment: Key Revenue Driver, More Than Fully Priced (NASDAQ:TEAM)

champja/iStock via Getty Images Investment Thesis Atlassian Corporation (NASDAQ:TEAM) helps teams work together more effectively. Their software products, like Jira and Confluence, are used for project management and collaboration. Atlassian’s platform helps businesses streamline their workflow and improve productivity by providing solutions for organizing tasks, and sharing information, and tracking progress on projects. It’s a…

Read More

Blackstone’s Acquisition Of Apartment Income REIT Is Likely Priced In

Mireya Acierto/DigitalVision via Getty Images Today’s article dials in on Apartment Income REIT Corp. (NYSE:NYSE:AIRC), a U.S.-based REIT targeting upmarket residential units. The rationale for this thesis stems from Blackstone’s (NYSE:BX) agreement to acquire Apartment Income REIT Corp. in a deal worth a reported $10 billion. Apartment Income REIT Corp.’s market price surged by more…

Read More

Mobileye (MBLY) Stock: Not Correctly Priced

Michael M. Santiago Despite a big warning for 2024, Mobileye Global Inc. (NASDAQ:MBLY) has already started an irrational rally back up to previous highs. The ADAS company has run into a questionable demand scenario due to the clouds of a major inventory issue. My investment thesis remains Bearish on the stock following the big rally…

Read More

bluebird bio Is Priced Below IP Value (NASDAQ:BLUE)

anusorn nakdee I am following up on my previous analysis for bluebird bio, Inc. (NASDAQ:BLUE) in light of the recent financing news. In November and just before the FDA announcement on Bluebird’s Sickle Cell treatment, I rated Bluebird a buy for the following reasons: FDA Approval was likely based on signaling. Cash flow was tight…

Read More

Copart Stock: How Much Of Its Growth Is Already Priced In? (NASDAQ:CPRT)

View from above of big parking lot with parked used cars after accident ready for sale. Auction reseller company selling secondhand broken vehicles for repair Bilanol/iStock via Getty Images Investment Thesis Since March 1994, when Copart (NASDAQ:CPRT) was listed in Nasdaq, the company has “rewarded” its shareholders with an incredible 24.000% return approximately. Even though…

Read More

Veeva Systems: Still Attractively Priced Given Growth Expectations (NYSE:VEEV)

sanjeri/E+ via Getty Images Investment Thesis Veeva Systems Inc. (NYSE:VEEV) helps streamline processes, improve collaboration, and ensure compliance with industry regulations. The business is highly entrenched and returning to attractive growth once again. Furthermore, I make the case that paying 32x forward non-GAAP operating profits for Veeva is attractively priced. Simply put, with more than…

Read More

Medpace: Exceptional Performance, Almost Fully Priced In (NASDAQ:MEDP)

AzmanJaka Medpace (NASDAQ:MEDP) is a fast-growing clinical research organization, focused on small biopharma customers, and is still founder-led by CEO August Troendle. Throughout the last year, particularly small biopharma companies increasingly faced financing issues due to the macroeconomic slowdown and rising interest environment. Additionally, we saw loaded inventories and therefore a normalization for equipment manufacturers….

Read More

Microsoft: Is AI Growth Priced In? (NASDAQ:MSFT)

Chris Hondros Business Overview Microsoft Corporation (NASDAQ:MSFT) started life as a technology leader. It has grown its revenues by developing technologies in-house through investments in research and development and by the acquisition of other innovative companies. Over the last 10 years, Microsoft has invested almost $172 billion in research and development (13% of revenues) and…

Read More

Comerica Is Fairly Priced Relative To Peers (NYSE:CMA)

JHVEPhoto Ahead of Comerica Incorporated’s (NYSE:CMA) newest earnings report on January 19th, I believe investors should sell the firm’s shares. My last article about Comerica, published on October 4th, argued that the bank had been unfairly beaten down following the March 2023 banking crisis. Moreover, the usage of intrinsic and extrinsic valuation methodologies confirmed the…

Read More

BILL Holdings Stock Faces Investor Caution While Being Priced At 40x EPS (NYSE:BILL)

Michael Vi Investment Thesis BILL Holdings (NYSE:BILL) simplifies financial operations for SMBs through specialized automation software, including payables and receivables management. The stock isn’t overly expensive at 40x forward EPS. The problem here is twofold. Firstly, the business is slowing down at a rapid rate, and it’s difficult to know with certainty at what rate…

Read More

CAVA Group: Too Many Risks Aren’t Priced In

Mario Tama CAVA Group (NYSE:CAVA), owner of a fast-growing contemporary Mediterranean food chain, checks every box when it comes to its potential to become America’s next big food chain. Showcasing a unique and healthy menu, and prudently managed with emphasis on exceptional operational efficiency and an employee satisfaction, CAVA’s management took a page from the…

Read More

On Holding: Positive Take Priced In (NYSE:ONON)

Orbon Alija Following our initiation of coverage of On Holding AG (NYSE: NYSE:ONON), today we are back to comment on the company results based on the Nike Q2 2024 readout and the latest news on the Sporting Goods sector. In this update, there are at least three takes on the read across from Nike’s September-November…

Read More

ImmunityBio: Approval Likely Priced In, Yielding Mostly Risk For Would-Be Buyers (IBRX)

Sebastian Gorczowski/iStock via Getty Images Topline Summary and Update ImmunityBio, Inc. (NASDAQ:IBRX) is a late-stage developmental biotech trying to bring novel immunotherapy approaches for cancer treatment to market. Their first and biggest shot on goal is a combination therapy with BCG in patients with bladder cancer, with an FDA decision coming in April 2024. While…

Read More

KSA: Fairly Priced (NYSEARCA:KSA) | Seeking Alpha

Abdullah Baloch/iStock via Getty Images Following up on my recent article on broad Emerging Market equities, this article examines the iShares MSCI Saudi Arabia ETF (NYSEARCA:KSA), an ETF dedicated to Saudi Arabian equities. Saudi Arabia Overview Saudi Arabia is the largest economy in the Middle East with a GDP of $1.1 trillion, ranking it 17th…

Read More

Crown Holdings: Profit Recovery, Inexpensively Priced (NYSE:CCK)

LordRunar Crown Holdings “Crown” (NYSE:CCK), with operations in beverage/food can and packaging manufacturing, has the business attributes that I generally seek out in an investable business. Some of those checkboxes include durability, defensibility, growth and an undemanding valuation. I originally purchased shares in November 2022 following the selloff related to its Q3 2022 report, which…

Read More

Paycor: Solid Execution Priced In (NASDAQ:PYCR)

vinnstock Investment Thesis Paycor HCM (NASDAQ:PYCR) had been affected due to a risk-off sentiment as macro slowdown makes the SMB segment, its core focus, more susceptible along with slowing employment growth. However, we really like the strong execution and follow through on earnings momentum in a challenging macro environment with stable retention ratios and strong…

Read More

Peter Schiff Predicts Bitcoin Crash as US ETF Frenzy Gets Slowly Priced In despite High Optimism

While Peter Schiff thinks Bitcoin price will crash before the ETF launch in the United States, analysts at AllianceBernstein issued a prediction of $150k in 2025 driven by the halving event and institutional inflows. The recent Bitcoin (BTC) breakout has significantly raised investors’ optimism for a continued bullish trend in the coming weeks toward the…

Read More

PROS Holdings: Too Much Growth Is Priced In (NYSE:PRO)

dongfang zhao/iStock via Getty Images PROS Holdings (NYSE:PRO) sells profit and revenue optimization software. The company has grown its revenues through a subscription-based model, with airlines representing a good portion of PROS’ revenues. Still, the company has negative earnings as a result of extensive R&D and marketing investments. PROS has taken cost control measures in…

Read More

Autodesk Stock: AI Capabilities Not Fully Priced In (NASDAQ:ADSK)

Laurence Dutton Overview Autodesk (NASDAQ:ADSK) notably underperformed the broader market last year, witnessing a stock decline of roughly 9% year-over-year. In comparison, the NASDAQ index (QQQ) saw an approximate rise of 27%. The continuous high-interest rate environment dampens the construction market’s pace, which continues to be Autodesk’s most significant market segment. Interestingly, Autodesk didn’t capitalize…

Read More

Salesforce: AI Expansion Already Well Priced Into Valuation (NYSE:CRM)

JasonDoiy Salesforce (NYSE:CRM) has been among the tech giants that integrated AI into its business model, specifically within its customer relationship management software. Throughout the year, Salesforce shares have surged by approximately 57%, driven by the AI revolution emphasized by CEO and founder Marc Benioff in the company’s recent earnings call. This surge reflects the…

Read More

DoubleVerify: Priced For Likely Great Performance (NYSE:DV)

anyaberkut DoubleVerify (NYSE:DV) provides advertising technology. The company has achieved a stable and high growth and has stayed profitable on a net income basis in the entire period, contrary to many growing software companies. DoubleVerify’s software offering seems to be very competitive in the ad-tech industry with multiple promising KPIs. Although the company is great…

Read More

CrowdStrike: Priced For Perfection (NASDAQ:CRWD)

da-kuk Shares of CrowdStrike Holdings (NASDAQ:CRWD) have seen a strong revaluation since December 2022 which is when I last worked on the cybersecurity company. CrowdStrike continued to grow in the last nine months as well, especially in regard to its top line expansion and the company maintained its customer acquisition momentum. However, shares now appear…

Read More